Home>>Signaling Pathways>> Neuroscience>> Amyloid β>>Aftin-4

Aftin-4

Catalog No.GC31259

An inducer of Aβ42

Products are for research use only. Not for human use. We do not sell to patients.

Aftin-4 Chemical Structure

Cas No.: 866893-90-5

Size Price Stock Qty
10mM (in 1mL DMSO)
$98.00
In stock
5mg
$121.00
In stock
10mg
$195.00
In stock
25mg
$389.00
In stock
50mg
$695.00
In stock
100mg
$1,205.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Aftin-4 is an Amyloid-β42 (Aβ42) inducer.

Aftin-4 selectively and potently increases Aβ1-42 in N2a cells, primary neurons, and brain lysates, with an EC50 value around 30 μM[1].

Aftin-4 increases Aβ1-42 levels in vivo in mice and provokes rapidly a sustained toxicity highly reminiscent of Alzheimer's disease (AD). Aftin-4 is administered at increasing doses, between 3 and 20 nmol/mouse, into the lateral ventricle and animals are sacrificed at various time points, between 3 to 14 days after injection. The hippocampus is dissected out the contents in Aβ1-40 or Aβ1-42 is determined using a mouse ELISA assay. Aftin-4 dose-dependently and significantly increases Aβ1-42 content, up to +216% at the highest dose tested[1].

[1]. Meunier J, et al. Brain toxicity and inflammation induced in vivo in mice by the amyloid-β forty-two inducer aftin-4, a roscovitine derivative. J Alzheimers Dis. 2015;44(2):507-24.

Reviews

Review for Aftin-4

Average Rating: 5 ★★★★★ (Based on Reviews and 34 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Aftin-4

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.